| CAS NO: | 2295-58-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 182.17 |
|---|---|
| Formula | C9H10O4 |
| CAS No. | 2295-58-1 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 36 mg/mL (197.61 mM) |
| Water: <1 mg/mL | |
| Ethanol: 36 mg/mL (197.61 mM) | |
| SMILES | CCC(C1=C(O)C=C(O)C=C1O)=O |
| Synonyms | Argobyl; Chlonarin; Cospanon; Ecapron; Flopion; Flopropion; Gallepronin; Gasstenon; Labroda |
| In Vitro | In vitro activity: Flopropione at temperatures below its T(g) shows no Lorentzian relaxation. Flopropione at temperatures below its T(g) has higher molecular mobility than Nifedipine. Flopropione shows Arrhenius temperature dependence throughout the entire temperature range and extrapolation of tau (beta) measured above T (g) by dielectric relaxation agreed with tau (beta) measured below T (g) by TAM/MDSC. |
|---|---|
| In Vivo | The effect of Flopropione as an antispasmodic agent on the rate of passing a calculus from the urinary tract has been compared retrospectively with patients in whom passage was spontaneous. Flopropine has been shown, with statistical significance, to be superior to the control in cumulative passage rate after initiation of administration. Flopropine has been shown to exert a spasmolytic effect not only on smooth muscle of the gastrointestinal tract but also on smooth muscle of the pancreatobiliary and urinary systems. |
| Animal model | |
| Formulation & Dosage | |
| References | J Pharm Sci. 2000 Mar;89(3):408-16; Pharm Res. 2006 Oct;23(10):2277-90. |
m.cnreagent.com